Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.

Autor:	Parker M; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Kazemi F; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Krishnakumar A; School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA., Horowitz MA; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Myneni S; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Liu A; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Schreck KC; Department of Neurology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA., Lucas CG; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Mukherjee D; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jazyk:	angličtina
Zdroj:	Journal of neuropathology and experimental neurology [J Neuropathol Exp Neurol] 2024 Jun 20; Vol. 83 (7), pp. 579-585.
DOI:	10.1093/jnen/nlae035
Abstrakt:	Advanced molecular testing has increasingly become an integral component for accurate diagnosis of central nervous system (CNS) tumors. We sought to establish the current state of molecular testing availability and approaches for the diagnosis of CNS tumors in US hospitals that conduct high volumes of CNS tumor resections. We distributed a 16-item survey inquiring about molecular testing approaches for CNS tumors to 115 neuropathologists at US hospitals with neurosurgery residency programs. Thirty-five neuropathologists (30.4%) responded to the survey, all of whom indicated their institutions perform molecular testing on CNS tumor tissue. The most commonly offered tests were MGMT methylation profiling and next-generation sequencing. Fourteen respondents (40%) indicated that their institution is able to test for and report all of the molecular alterations included in our survey. Nine (25.7%) respondents indicated that molecular testing is performed as standard of care for all patients with resected CNS tumors. Our results suggest that even in academic hospitals with a high volume of CNS tumor resections, molecular testing for these tumors is limited. Continued initiatives are necessary to expand the availability of molecular testing for CNS tumors to ensure diagnostic accuracy and guide targeted therapy. (© The Author(s) 2024. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu